Adenocarcinoma of urachus report of 7 cases and review of literature

Kakizoe, Tadao; Matsumoto, Keīichi; Andoh, Masashi; Nishio, Yasunori; Kishi, Kiyozo

doi:10.1016/0090-4295(83)90152-8

Cited by 74 publications

(26 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar to other studies, we observed that neither age nor gender were predictors of outcome. [3][4][5] To our knowledge, the current study presents the first multivariate analysis of predictors of malignancy in patients with clinically diagnosed urachal masses. We observed that, if a patient was older than age 55 years at diagnosis, then the probability that their urachal mass was malignant tripled.…”

Section: Discussionmentioning

confidence: 99%

“…carcinoma is generally poor, because their tumors often are not diagnosed until late in the course of the disease. [2][3][4][5] In this article, we review all urachal carcinomas that were diagnosed and treated at the Mayo Clinic over the last 50 years. We present a comprehensive description of urachal carcinomas and describe several novel findings, including, 1) predictors of malignancy for clinically diagnosed urachal masses, 2) prognostic factors for urachal cancer-specific survival, 3) a simplified pathologic staging system, 4) a presentation of the natural history of urachal carcinomas treated at different disease stages, and 5) evidence of the efficacy of salvage treatment for urachal cancers that recur locally after primary treatment.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Urachal carcinoma: Clinicopathologic features and long‐term outcomes of an aggressive malignancy

Ashley

Inman

Sebo

et al. 2006

Cancer

289

413

View full text Add to dashboard Cite

Objective L‐dopa is the most widely used and most effective therapy for Parkinson disease (PD), but chronic treatment is associated with motor complications in the majority of patients. It has been hypothesized that providing more continuous delivery of L‐dopa to the brain would reduce the risk of motor complications, and that this might be accomplished by combining L‐dopa with entacapone, an inhibitor of catechol‐O‐methyltransferase, to extend its elimination half‐life. Methods We performed a prospective 134‐week double‐blind trial comparing the risk of developing dyskinesia in 747 PD patients randomized to initiate L‐dopa therapy with L‐dopa/carbidopa (LC) or L‐dopa/carbidopa/entacapone (LCE), administered 4× daily at 3.5‐hour intervals. The primary endpoint was time to onset of dyskinesia. Results In comparison to LC, patients receiving LCE had a shorter time to onset of dyskinesia (hazard ratio, 1.29; p = 0.04) and increased frequency at week 134 (42% vs 32%; p = 0.02). These effects were more pronounced in patients receiving dopamine agonists at baseline. Time to wearing off and motor scores were not significantly different, but trended in favor of LCE treatment. Patients in the LCE group received greater L‐dopa dose equivalents than LC‐treated patients (p < 0.001). Interpretation Initiating L‐dopa therapy with LCE failed to delay the time of onset or reduce the frequency of dyskinesia compared to LC. In fact, LCE was associated with a shorter time to onset and increased frequency of dyskinesia compared to LC. These results may reflect that the treatment protocol employed did not provide continuous L‐dopa availability and the higher L‐dopa dose equivalents in the LCE group. ANN NEUROL 2010;68:18–27

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Urachal carcinoma: Clinicopathologic features and long‐term outcomes of an aggressive malignancy

Ashley

Inman

Sebo

et al. 2006

Cancer

289

413

View full text Add to dashboard Cite

show abstract

“…17 The review of activity with typical transitional cell-oriented chemotherapy suggests little benefit, with few responses reported with combinations such as M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) and gemcitabine-cisplatin. 2 However, as early as 1985 Logothetis et al saw evidence of activity with a combination of 5-fluorouracil, doxorubicin, and mitomycin, reporting partial responses in two of three patients.…”

Section: Systemic Chemotherapymentioning

confidence: 98%

Urachal Adenocarcinoma: A Clinician's Guide for Treatment

Siefker-Radtke

2012

Seminars in Oncology

123

119

View full text Add to dashboard Cite

“…These 25 cases were received between 1981 and 2001. The CT images were evaluated to determine ] tumor morphology (cyst vs. solid) [1], presence [2] and localization [3] of calcification, extent of bladder invasion [4] and metastases [5]. The pathology and surgical reports were reviewed for all patients.…”

Section: Methodsmentioning

confidence: 99%

“…Less common histologic types include transitional cell and squamous cell carcinoma. Several reviews have discussed the clinical aspects of urachal carcinoma [3][4][5]. Because of the rarity of this tumor, the radiological literature consists primarily of case reports and small series [6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Computed tomographic appearance of urachal adenocarcinomas: review of 25 cases

2004

View full text Add to dashboard Cite

Twenty-five cases of surgically proven urachal carcinomas were retrospectively reviewed. The radiological archives at the Armed Forces Institute of Pathology were searched for cases of surgically proven urachal carcinomas that had a computed tomographic (CT) scan as a part of their radiologic evaluation. CT images from all cases were evaluated to determine tumor morphology, presence and localization of calcification, extent of bladder invasion and metastases. Tumor size at presentation averaged 6 cm. Twentyone of 25 (84%) were mixed cystic solid lesions and 4/25 (16%) were completely solid. Calcifications were present in 18/25 (72%), with 11 peripherally located, 3 central only and 4 both. Bladder wall invasion was present in 23/25 (92%), but was seen as an intraluminal mass in only 13/25 (52%). The bulk of the mass was extravesicular in 22/25 (88%). Metastases were present in 12/25 (48%). Our series supports observations from other smaller series that a midline, calcified, supravesicular mass is highly suspicious, if not pathognomonic, for urachal carcinoma.

show abstract

Adenocarcinoma of urachus report of 7 cases and review of literature

Cited by 74 publications

References 13 publications

Urachal carcinoma: Clinicopathologic features and long‐term outcomes of an aggressive malignancy

Urachal carcinoma: Clinicopathologic features and long‐term outcomes of an aggressive malignancy

Urachal Adenocarcinoma: A Clinician's Guide for Treatment

Computed tomographic appearance of urachal adenocarcinomas: review of 25 cases

Contact Info

Product

Resources

About